Unlearn

San Francisco, CA, United States All United States companies → — Founded 2017

AI Research Lab Biotech / Drug Discovery

Cardiology Neurology Oncology

Drug Discovery & Research

Series C

Website Claim this company

Products

Unlearn (Scout, Hindsight, SimLab)

Unlearn

Drug Discovery & Research

Unlearn leverages AI and digital twin technology to streamline clinical development, enabling faster, more robust studies, and bringing life-saving treatments to patients sooner.

Not disclosed

See all 1 product →

About Unlearn

Unlearn is a healthcare AI company that is revolutionizing clinical trials through the creation and application of “digital twins” of patients. For physicians, this means a significant advancement in how new treatments are developed and evaluated. Unlearn’s proprietary technology, including its DiGenesis™ process and TwinRCTs™, utilizes generative AI models to create simulated clinical records that predict individual health outcomes under various treatment scenarios. This allows for the development of intelligent control arms in clinical studies, reducing the need for large placebo groups and enabling more patients to receive potentially beneficial experimental treatments.

The core benefit for the medical community is the acceleration and ethical improvement of clinical research. By leveraging digital twins, Unlearn aims to make clinical trials faster, smaller, and more efficient, ultimately bringing life-saving therapies to patients sooner. The company’s methods have received qualification from the European Medicines Agency (EMA) and align with FDA guidance, indicating a robust and credible scientific approach. This technology can also assist healthcare professionals in personalizing treatment plans, monitoring patient progress, and making more informed decisions by simulating the effects of different treatments on an individual patient’s biology.

Focus Areas

AI in clinical trials digital twins synthetic control arms drug development neurodegenerative diseases oncology biostatistics machine learning

Business Intelligence

Technology

AI-powered digital twin technology, generative machine learning models, proprietary DiGenesis™ process, PROCOVA™ (Prognostic Covariate Adjustment) statistical approach, TrialPioneer (unified workspace for trial planning)

At a glance

Founded 2017

HQ San Francisco, CA, United States · United States

CEO Steve Herne

Funding Series C

Products 1

Visit site

Products by Unlearn

1 product in the directory

Unlearn (Scout, Hindsight, SimLab)

Unlearn

Drug Discovery & Research

Unlearn leverages AI and digital twin technology to streamline clinical development, enabling faster, more robust studies, and bringing life-saving treatments to patients sooner.

Not disclosed

Reviews & Opinions

No web reviews on file yet for Unlearn. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Unlearn.

Loading videos...

Videos load interactively. If none appear, search YouTube for Unlearn →

View all on YouTube

Press & Coverage

Business Wire

Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technology

Unlearn announced a $50M Series C funding round led by Altimeter Capital to advance its mission of eliminating trial and error in medicine through AI-powered digital twins for clinical trials. The funding will support investments in people, data, engineering capabilities, and R&D initiatives.

2024-02

Fierce Biotech

Digital twin developer Unlearn sees double with 2nd $50M venture capital round

Unlearn secured another $50 million in a Series C funding round, bringing its total fundraising to over $130 million. The company's AI analyzes patient health records to create digital twins, which predict patient outcomes in placebo groups, allowing for smaller control groups in clinical trials.

2024-02

BioSpace

European Medicines Agency Qualifies Unlearn's AI-powered Method for Running Smaller, Faster Clinical Trials

Unlearn announced that the European Medicines Agency (EMA) has issued a favorable qualification opinion for its TwinRCTu2122 solution, providing a regulatory framework for using its AI-powered prognostic digital twins in Phase 2 and 3 clinical trials. This marks the first time a regulatory body has formally supported a machine learning-based method for reducing sample size in pivotal trials.

2022-09

Clinical and Translational Science

Increasing acceptance of AI-generated digital twins through clinical trial applications

This peer-reviewed article discusses the increasing acceptance of AI-generated digital twins in clinical trial applications, highlighting their potential to support rapid evaluation of intervention strategies and accelerate drug development. The authors contend that the regulatory outlook for this technology makes it an ideal setting for safe AI application in healthcare.

2024-07

Business Wire

Unlearn's 2024 Achievements Drive Innovation in AI for Clinical Development

Unlearn achieved significant milestones in 2024, including securing $50M in Series C funding, launching innovative tools like TrialPioneer, and forming strategic partnerships to address challenges in clinical research. The company also saw a leadership change with Steve Herne appointed as CEO to scale product offerings.

2024-12

Newswire

Unlearn Advances Huntington's Disease AI Modeling Through Access to CHDI Foundation Data

Unlearn announced its use of data from CHDI Foundation, Inc. to refine and update its Huntington's disease-specific Digital Twin Generator (HD DTG). This collaboration aims to improve the design and analysis of Huntington's disease trials using AI-generated digital twins.

2026-02

Business Wire

Unlearn and Trace Neuroscience Partner to Optimize ALS Clinical Trial

Unlearn is collaborating with Trace Neuroscience to optimize an upcoming Phase 1/2 clinical trial in amyotrophic lateral sclerosis (ALS) using Unlearn's Digital Twin Generator for ALS (ALS DTG) and the Unlearn Platform. This partnership aims to refine trial design, shorten timelines, and increase the chance of detecting treatment effects.

2025-04

Unlearn.AI Blog

How Unlearn is building a scientific intelligence layer for clinical development

Aaron Smith, founder and head of AI at Unlearn, discusses the company's development of a scientific intelligence layer that connects digital twin models, patient-level data, and historical literature to aid clinical teams in trial planning, monitoring, and analysis. He also highlights Unlearn's PROCOVA method, which has received EMA qualification and aligns with FDA guidance.

2026-06

Frequently Asked Questions

What exactly are Unlearn's 'digital twins' and how do they impact clinical trials?

Unlearn's 'digital twins' are AI-generated forecasts of individual clinical trial participants' expected control outcomes. By creating these virtual patient models, Unlearn aims to reduce the required sample sizes for control arms, accelerate trial timelines, and improve the ability to detect treatment effects in studies, particularly in early-stage and open-label trials.

How does Unlearn's technology address the ethical and logistical concerns of traditional clinical trial control arms?

Unlearn's technology addresses these concerns by generating synthetic control arms using digital twins. This approach can reduce the need for large placebo groups, allowing more patients to receive the experimental treatment, which is particularly beneficial in rare diseases or when patients are desperate for new therapies.

In which therapeutic areas has Unlearn demonstrated the most impact, particularly concerning neurodegenerative diseases and oncology?

Unlearn has shown significant impact in neurodegenerative diseases, with partnerships and studies focused on conditions like ALS, Alzheimer's disease, and Huntington's disease. While their vision is broader, their visible use cases have been concentrated in these neurological areas, as well as some work in immunology and metabolic disorders.

What regulatory acceptance has Unlearn received for its AI and digital twin methodologies in clinical trials?

Unlearn's methods have received recognition and support from both U.S. and European regulators. The European Medicines Agency (EMA) has officially qualified their PROCOVAu2122 method for use in Phase 2 and 3 trials with continuous outcomes, and the U.S. FDA has provided positive feedback supporting its use in covariate-adjusted analyses.

What are Unlearn's key products or solutions for optimizing drug development and clinical trial planning?

Unlearn offers a suite of solutions including TrialPioneer, an AI-powered workspace for upstream trial planning; Scout, for continuously searching and summarizing relevant literature and regulatory precedent; and Hindsight, for exploring harmonized clinical trial and real-world datasets to validate assumptions. Their core technology involves Digital Twin Generators (DTGs) for forecasting individual disease progression.

What is Unlearn's business model and how is pricing typically structured for healthcare organizations?

While specific pricing details are not publicly disclosed, Unlearn partners with pharmaceutical and biotech companies. Their technology aims to reduce clinical trial costs by 30-50% through virtual patient cohort simulation, suggesting a value-based model tied to efficiency gains and accelerated drug development.

What is the current stability and growth outlook for Unlearn, and who are their notable partners?

Unlearn shows solid momentum with strengths in innovation, funding, and partner traction, though scalability will depend on broader deployments beyond current flagship areas. They have secured significant funding, including a $50 million Series C round. Notable partners include Merck KGaA, AbbVie, Johnson & Johnson Innovative Medicine, VectorY Therapeutics, remynd, Trace Neuroscience, and ProJenX.